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ABSTRACT
Achromobacter xylosoxidans is a Gram-negative aerobic bacterium first described by Yabuuchi and Ohyama in 1971. 
A. xylosoxidans is frequently found in aquatic environments. Abdominal, urinary tract, ocular, pneumonia, meningitis, 
and osteomyelitis are the most common infections. Infective endocarditis is rare. As far as we know, until now, only 
19 cases have been described, including this current report. We report the case of community-acquired native valve 
endocarditis caused by A. xylosoxidans in an elderly patient without a concomitant diagnosis of a malignancy or any 
known immunodeficiency. The patient presented with a 2-month history of fever, weight loss, and progressive dyspnea. 
On physical examination, mitral and aortic murmurs were present, along with Janeway’s lesions, and a positive blood 
culture for A. xylosoxidans. The transesophageal echocardiogram showed vegetation in the aortic valve, which was 
consistent with the diagnosis of infective endocarditis. 
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CASE REPORT
An 86-year-old woman with heart failure due 
to ischemic heart disease, polymyalgia rheumatica, 
idiopathic pulmonary fibrosis, non-dialysis-dependent 
chronic kidney disease and panic disorder was 
brought to the emergency room with a 2-month 
history of persistent daily high-grade fever (38.5 °C) 
and progressive dyspnea. She had been previously 
hospitalized for 15 days because of fever and dyspnea 
accompanied by a cough and hyaline sputum, when 
the laboratory work-up revealed a positive blood 
culture for Achromobacter xylosoxidans. At that time, 
there was no evidence of vegetation on a transthoracic 
echocardiogram (TTE), no abnormality on the abdominal 
ultrasound or on the chest and abdominal computed 
tomography (CT). Also, she had a normal urinalysis 
and a negative urine culture. HIV, hepatitis B and C 
serology, and antinuclear antibodies were negative. 
The patient received an 8-day course of intravenous 
trimethoprim-sulfamethoxazole according to the blood 
culture sensitivity tests, followed by a 6-day course 
of the same orally administered antibiotic. She was 
discharged without fever, but the dyspnea remained 
unchanged.
On the eighth day following the withdrawal of the 
antibiotic, the fever relapsed and the patient restarted 
empirical treatment with the same antibiotic. Despite 
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this new regimen of antibiotic, she was readmitted with 
a high-grade fever, progressive worsening of dyspnea, 
and new skin lesions on the palms of her hands and 
soles of her feet. Over the previous 2 months, she 
had lost 5 kg (10% of her usual weight). She denied 
any previous diagnosis of malignancy, and any use of 
intravascular devices or immunosuppressive therapy. 
She was regularly using carvedilol, atorvastatin, and 
aspirin, besides the previously mentioned antibiotic 
when readmitted.
During the physical examination, she was pale, 
with tachycardia (pulse of 108 bpm), blood pressure 
of 98/60 mmHg and normal axillary temperature of 
36.8 °C. A systolic and diastolic cardiac murmur in 
the aortic area, and a systolic murmur in the mitral 
area, were easily audible. Pulmonary auscultation 
detected Velcro-like crackles, which were consistent 
with pulmonary fibrosis. The abdominal examination 
was painless; the liver was palpable at the right rib 
cage; the spleen was not palpable; and there was 
no dullness on percussion over the Traube’s space. 
Multiple non-tender erythematous violaceous papules 
and macules were present in the patient’s palms, 
fingers, thumbs, and soles, which was consistent with 
Janeway’s lesions (Figure 1). The patient had a total 
dental prosthesis and the oral cavity was free of lesions. 
Upon readmission, trimethoprim-sulfamethoxazole 
was withdrawn and three sets of blood cultures were 
sampled at different puncture sites at 12-hour intervals.
The initial laboratory work-up showed an elevated 
C-reactive protein level of 120 mg/L (reference value 
[RV]: <5 mg/L) and an erythrocyte sedimentation 
rate at 170 mm/h (RV: <20 mm/h), normocytic and 
Figure 1. Janeway’s lesions in the patient’s hand.
normochromic anemia, thrombocytosis, a positive 
rheumatoid factor of 60 UI/mL (RV: <16 UI/mL) and a 
serum creatinine of 1.59 mg/dL (RV: 0·4-1.3 mg/dL), 
which was similar to the patient’s previous creatinine 
determination; normal complement levels (C3 and C4) 
and a positive qualitative cryoblobulin’s test. Urinalysis 
showed microscopic hematuria without erythrocyte 
dysmorphism and mild proteinuria. All blood culture 
sets were negative. A TTE was performed on the 
second day following readmission, which did not show 
any valvular vegetation. However, a left ventricular 
systolic dysfunction and aortic and mitral regurgitation 
were found.
During the first 2 days of hospitalization, the 
patient remained afebrile, but on the third and fourth 
day she presented an ongoing axillary temperature of 
38.3 °C. Treatment with piperacillin-tazobactam was 
scheduled for a 6-week regimen. Another thoracic and 
abdominal CT was performed, ruling out any suspected 
site of infection or malignancies. A transesophageal 
echocardiography (TEE) showed a 4 mm vegetation on 
the non-coronary cusp of the aortic valve.
During hospitalization, the patient presented 
worsening signs of heart failure, including weight gain, 
sacral and lower limbs pitting edema, bilateral rales 
crackles, and hepatojugular reflux, which improved 
with diuretics and vasodilators titration. Furthermore, 
she presented five episodes of supraventricular 
tachycardia, which was treated with amiodarone. She 
completed a 6-week course of piperacillin-tazobactam 
along with improved clinical and laboratorial status. 
Her fever subsided after the 15th day of antibiotic 
treatment; the arrhythmia remained controlled and 
the heart failure became asymptomatic. She was 
discharged after 55 days of hospitalization for an 
outpatient clinical follow-up.
A signed informed consent for publication was 
obtained, and the manuscript is in accordance with 
the institution’s ethics committee.
DISCUSSION
Achromobacter xylosoxidans is a Gram-negative 
aerobic bacterium first described by Yabuuchi and 
Ohyama in 1971 in patients with chronic purulent 
otitis media.1 A. xylsoxidans is frequently found in 
aquatic environments2 and infections are frequently 
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associated with cardiovascular disease, malignancy, and 
immunosuppression,3,4 and are mostly a nosocomial 
infection.3 Pneumonia, meningitis, osteomyelitis, plus 
urinary tract, abdominal, and ocular are the most usual 
infections, while native valve endocarditis is rarely 
reported.2
Searching in the PubMed, Sc ie lo,  L i lacs, 
Scopus, and Web of Knowledge using the keywords 
“Achromobacter xylosoxidans” and “infective 
endocarditis” (IE) we were able to retrieve only 
18 cases of A. xylosoxidans endocarditis in the English 
language (Table 1). In our review, including our case, 
6 of 19 (32%) patients were 60 years old or older; 
3/19 (16%) were intravenous drug users; 3/19 (16%) 
had intravenous devices; 8/19 (42%) had prosthetic 
valve involvement. Considering the treatment and 
the outcome: 11 of 19 (58%) required surgical 
intervention; 8/17 (47%) died, 2 of the 8 (22%) were 
from the operated group and the other 6 (75%) were 
from the clinically treated group.
IE presents an incidence of 3.6/100,000 population/
year,22 and its diagnosis remains challenging since new 
AF: atrial fibrillation; Ao: Aortic; CABG: coronary artery bypass grafting; CHB: complete heart block; CHF: congestive heart 
failure; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; CS: cardiac surgery; DM: diabetes 
mellitus; H: Hipertension; HF: heart failure; IDU: intravenous drug user; IHD: ischemic heart disease; IS: ischemic stroke; 
IVC: intravenous catheter; M: Mitral; NA: not available; P: Pulmonary; PM: Pacemaker; PV: prosthetic valve; RVOT: right 
ventricular outflow tract; T: Tricuspid; TIA: transient ischemic accident; TMP-SMX: trimethoprim-sulfamethoxazole; 
TR: tricuspid regurgitation; VSDR: ventricular septal defect repair.
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No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
No
Yes
No
Yes
Yes
No
Yes
Yes
No
Sur-
gery
Yes
Yes
Yes
Yes
No
No
NA
No
Yes
Yes
Yes
No
Yes
No
No
No
No
NA
No
Died
Table 1. Reported cases of Achromobacter xylosoxidans IE
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etiologic agents have been increasingly reported. 
Similarly, the incidence of IE is increasing in the elderly 
population, which may present non-characteristic 
clinical symptoms, such as fatigue, malaise, and 
anorexia.23 Major clinical societies recommend the 
use of the Modified Duke Criteria,24 which is based 
on pathological and clinical findings.25 Considering 
the case reported herein, the patient had a previous 
hospitalization with fever and dyspnea and, on 
the second hospitalization, presented four minor 
clinical Duke’s criteria;24 namely, (i) Janeway’s lesions; 
(ii) positive rheumatoid factor; (iii) fever; and (iv) a 
positive blood culture on the previous hospitalization.
Therefore, the patient’s condition was classified 
as a “possible IE.” An initial TTE did not show any 
evidence of vegetation. However, as the patient had 
a high pre-test probability of IE, a TEE was performed, 
which evidenced cardiac vegetation on the aortic 
valve. The diagnosis of IE was made on the basis of the 
presence of four minor and one major clinical Modified 
Duke Criteria.24 TTE identifies only 25% of vegetation 
<5 mm while TEE for all vegetation sensitivity ranges 
between 90% and 100%.26-28 Vegetation size is 
associated with the risk of embolism and vegetation 
>1 cm is a predictive value for mortality risk in patients 
over 60 years of age.29,30
In 1986, the review made by Chandrasekar et al.,31 
regarding A. xylosoxidans  bacteremia, found 
resistance to aminoglycosides and a susceptibility 
to trimethoprim-sulfamethoxazole and beta-lactam 
antibiotics. Subsequently, two other reviews (by 
Duggan et al.4 in 1996 and Gómez-Cerezo et al.3 in 2003) 
found susceptibility to antipseudomonal penicillins 
and carbapenems, and resistance to aminoglycosides 
and second-generation cephalosporins. Duggan4 
found that trimethoprim-sulfamethoxazole was 
bacteriostatic and Gómez-Cerezo3 found resistance to 
this antibiotic. Two recent case reports of infections 
due to A. xylosoxidans found additional susceptibility 
to amoxicillin-clavulanate.32,33 Due to the scarcity 
of the cases reported, there is no consensus on 
the best antimicrobial regimen for endocarditis 
caused by A. xylosoxidans. However, it seems that 
antipseudomonal penicillins and carbapenems are the 
best choice, based on bacteremia studies and case 
reports.2-7,9-11,13-16,31
In our case report, the patient had a community-
acquired, native-valve IE, which was attributed to this 
pathogen. She also had cardiovascular disease, which 
is a risk factor for A. xylosoxidans infection, but the 
site involved (cardiac) is unusual for this bacteria. When 
the fever recurred, we started a piperacillin-tazobactam 
regimen based on the antibiogram and the available 
literature data. The patient had a favorable response 
to the antibiotic course and was discharged without 
any other symptoms.
IE in the elderly can have mild symptoms and 
diagnosis can be very challenging. This report 
emphasizes the necessity to investigate patients with 
long-lasting fever and validates positive blood cultures, 
even with uncommon bacterium. It also highlights that 
clinicians should consider the diagnosis of IE and the 
performance of a TTE when most of the common sites 
of infection were ruled out.
REFERENCES
1. Yabuuchi E, Oyama A. Achromobacter xylosoxidans 
n. sp. from human ear discharge. Jpn J Microbiol. 
1971;15(5):477-81. PMid:5316576. http://dx.doi.
org/10.1111/j.1348-0421.1971.tb00607.x. 
2. Derber  C,  E lam K,  Forbes  BA,  Bearman G. 
Achromobacter species endocarditis: a case report 
and literature review. Can J Infect Dis Med Microbiol. 
2011;22(3):e17-20. PMid:22942890. http://dx.doi.
org/10.1155/2011/527412. 
3. Gómez-Cerezo J, Suárez I, Ríos JJ, et al. Achromobacter 
xylosoxidans bacteremia: a 10-year analysis of 54 
cases. Eur J Clin Microbiol Infect Dis. 2003;22(6):360-3. 
PMid:12750959. http://dx.doi.org/10.1007/s10096-003-
0925-3. 
4. Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman 
CA, Bradley SF. Achromobacter xylosoxidansbacteremia: 
report of four cases and review of the literature. Clin 
Infect Dis. 1996;23(3):569-76. PMid:8879782. http://
dx.doi.org/10.1093/clinids/23.3.569. 
5. Kumar S, Khaira J, Penigalapati D. Native valve 
endocarditis in a dialysis patient by Achromobacter 
xylosoxidans: Rare pathogen. Open Forum Infect Dis. 
2016;3(Suppl 1):1106. http://dx.doi.org/10.1093/ofid/
ofw172.809. 
6. Bhattarai M, Papireddy M, Kulkarni S. A rare case of 
complicated Achromobacter xylosoxidans endocarditis and 
its successful management. J Hosp Med. 2016;11(Suppl 
1). [cited 2017 Apr 28]. Available from: http://www.
shmabstracts.com/abstract/a-rare-case-of-complicated-
achromobacter-xylosoxidans-endocarditis-and-its-
successful-management/ 
Native-valve endocarditis caused by Achromobacter xylosoxidans: a case report and review of literature
54 Autops Case Rep (São Paulo). 2017;7(3):50-55
7. Levoy CS, Hall DJ, Berman D. Achromobacter xylosoxidans 
endocarditis and septic arthritis in an infant affected by 
generalized arterial calcification of infancy. JMM Case Rep. 
2015;2(6) http://dx.doi.org/10.1099/jmmcr.0.005006. 
8. Rafael AE, Keshavamurthy S, Sepulveda E, Miranda CC, 
Okamoto T, Pettersson GB. Intracardiac abscess with 
cutaneous fistula secondary to ventricular septal defect 
repair simulating sternal wound infection. Tex Heart 
Inst J. 2014;41(3):324-6. PMid:24955054. http://dx.doi.
org/10.14503/THIJ-13-3199. 
9. Sawant AC, Srivatsa SS, Castro LJ. Alcaligenes xylosoxidans 
endocarditis of a prosthetic valve and pacemaker. Tex 
Heart Inst J. 2013;40(1):95-8. PMid:23466992.
10. Tokuyasu H, Fukushima T, Nakazaki H, Shimizu E. 
Infective endocarditis caused by Achromobacter 
xylosoxidans: a case report and review of the literature. 
Intern Med. 2012;51(9):1133-8. PMid:22576403. http://
dx.doi.org/10.2169/internalmedicine.51.6930. 
11. Storey A, Wilson A, McWilliams E. Native valve infective 
endocarditis due to Achromobacter xylosoxidans in an 
apparently immunocompetent individual. BMJ Case 
Rep. 2010;2010(1):1. PMid:22798095. http://dx.doi.
org/10.1136/bcr.06.2010.3104. 
12. Malek-Marín T, Arenas MD, Perdiguero M, et al. A case of 
endocarditis of difficult diagnosis in dialysis: could “pest” 
friends be involved? Clin Nephrol. 2009;72(5):405-9. 
PMid:19863886. http://dx.doi.org/10.5414/CNP72405. 
13. Ahmed MS, Nistal C, Jayan R, Kuduvalli M, Anijeet HK. 
Achromobacter xylosoxidans, an emerging pathogen 
in catheter-related infection in dialysis population 
causing prosthetic valve endocarditis: a case report and 
review of literature. Clin Nephrol. 2009;71(3):350-4. 
PMid:19281752. http://dx.doi.org/10.5414/CNP71350. 
14. Van Hal S, Stark D, Marriott D, Harkness J. Achromobacter 
xylosoxidans subsp. xylosoxidans prosthetic aortic valve 
infective endocarditis and aortic root abscesses. J Med 
Microbiol. 2008;57(Pt 4):525-7. PMid:18349376. http://
dx.doi.org/10.1099/jmm.0.47496-0. 
15. Yang CH, Shih NC, Lu DCT. Infective endocarditis 
due to Achromobacter xylosoxidans associated with 
spondylodiscitis: a case report. J Int Med Taiwan. 
2007;18(4):212-6.
16. Nanuashvili A, Kacharava G, Jashiashvili N. A case of native 
valve endocarditis caused by Alcaligenes xylosoxidans. 
Euro Surveill. 2007;12(5):1. PMid:17868590.
17. Ahn Y, Kim NH, Shin DH, et al. Pacemaker lead 
endocarditis caused by Achromobacter xylosoxidans. 
J Korean Med Sci. 2004;19(2):291-3. PMid:15082906. 
http://dx.doi.org/10.3346/jkms.2004.19.2.291. 
18. Martino P, Micozzi A, Venditti M, et al. Catheter-
related right-sided endocarditis in bone marrow 
transplant recipients. Rev Infect Dis. 1990;12(2):250-
7.  PMid:2330480. http: / /dx.doi .org/10.1093/
clinids/12.2.250. 
19. Davis M, Gratten M, Ree GH. Infective endocarditis 
cause by Actinobacillus actinomycetemcomitans and 
Achromobacter xylosoxidans. P N G Med J. 1982;25(1):7-
11. PMid:6957084.
20. Olson DA, Hoeprich PD. Postoperative valve endocarditis 
due to Achromobacter xylosoxidans. West J Med. 
1982;136(2):153-7. PMid:7064475.
21. Lofgren RP, Nelson AE, Crossley KB. Prosthetic valve 
endocarditis due to Achromobacter xylosoxidans. Am 
Heart J. 1981;101(4):502. PMid:7211679. http://dx.doi.
org/10.1016/0002-8703(81)90144-7. 
22. Prendergast BD. The changing face of infective 
endocarditis. Heart. 2006;92(7):879-85. PMid:16216860. 
http://dx.doi.org/10.1136/hrt.2005.067256. 
23. Gregoratos G. Infective endocarditis in the elderly: 
diagnosis and management. Am J Geriatr Cardiol. 
2003;12(3):183-9. PMid:12732814. http://dx.doi.
org/10.1111/j.1076-7460.2003.02073.x. 
24. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to 
the Duke criteria for the diagnosis of infective endocarditis. 
Clin Infect Dis. 2000;30(4):633-8. PMid:10770721. http://
dx.doi.org/10.1086/313753. 
25. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC 
Guidelines for the management of infective endocarditis. 
Eur Heart J. 2015;36(44):3036-7. PMid:26590409. http://
dx.doi.org/10.1093/eurheartj/ehv319. 
26. Evangelista A, Gonzalez-Alujas MT. Echocardiography 
in infective endocarditis. Heart. 2004;90(6):614-
7. PMid:15145856. http://dx.doi.org/10.1136/
hrt.2003.029868. 
27. Erbel R, Rohmann S, Drexler M, et al. Improved diagnostic 
value of echocardiography in patients with infective 
endocarditis by transesophageal approach. A prospective 
study. Eur Heart J. 1988;9(1):43-53. PMid:3345769. 
http://dx.doi.org/10.1093/ehj/9.1.43. 
28. Shapiro SM, Young E, De Guzman S, et al. Transesophageal 
echocardiography in diagnosis of infective endocarditis. 
Chest. 1994;105(2):377-82. PMid:8306732. http://
dx.doi.org/10.1378/chest.105.2.377. 
29. Luaces M, Vilacosta I, Fernández C, et al. Vegetation 
size at diagnosis in infective endocarditis: influencing 
factors and prognostic implications. Int J Cardiol. 
2009;137(1):76-8. PMid:18694604. http://dx.doi.
org/10.1016/j.ijcard.2008.05.011. 
30. Leitman M, Dreznik Y, Tyomkin V, Fuchs T, Krakover 
R, Vered Z. Vegetation size in patients with infective 
endocarditis. Eur Heart J Cardiovasc Imaging. 
2012;13(4):330-8. PMid:22109247. http://dx.doi.
org/10.1093/ejechocard/jer253. 
Rodrigues CG, Rays J, Kanegae MY
55Autops Case Rep (São Paulo). 2017;7(3):50-55
31. Chandrasekar PH, Arathoon E, Levine DP, Chandrasekar 
PH. Infections due to Achromobacter xylosoxidans. Case 
report and review of literature. Infection. 1986;14(6):279-
82. PMid:3818105. http://dx.doi.org/10.1007/
BF01643962. 
32. Raghuraman K, Ahmed NH, Baruah FK, Grover RK. 
Achromobacter xylosoxidans: bloodstream infection in an 
elderly patient with hepatocellular carcinoma: case report 
and review of the literature. J Lab Phys. 2015;7(2):124-7. 
PMid:26417165.
33. Ng ZY, Fang G, Leo KW. Resolution of concomitant 
Achromobacter xylosoxidans burn wound infection 
without adjustment of antimicrobial therapy. Indian J 
Plast Surg. 2014;47(1):137-40. PMid:24987220. http://
dx.doi.org/10.4103/0970-0358.129650. 
Author contributions: Rodrigues CG, Rays J and Kanegae MY were the assistance of the patient; worked 
together reviewing the literature; writing the manuscript; analyzing and interpreting the data. All the authors 
approved the final version to be published.
Conflict of interest: None
Financial support: None
Submitted on: April 28th, 2017 
Accepted on: June 12th, 2017
Correspondence 
Caio Godoy Rodrigues 
Internal Medicine Department - School of Medicine - University of São Paulo (USP) 
Rua Capote Valente, 188, ap. 61 – Pinheiros – São Paulo/SP – Brazil 
CEP: 05409-000 
Phone: +55 (11) 98919-6893 
caiogrod@gmail.com
